Zcash (ZEC) is up 24% this week, approaching key resistance at $472 as whales accumulate, retail sells, and a new fee model is proposed.Zcash (ZEC) is up 24% this week, approaching key resistance at $472 as whales accumulate, retail sells, and a new fee model is proposed.

Zcash (ZEC) Price Jumps 24% Weekly: Is $616 the Next Target?

2025/12/09 17:28
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Zcash (ZEC) is trading at around $418 after rising 13% in the last 24 hours. Over the past week, the price is up by 24%.

Consequently, the move follows a breakout from a technical setup where price cleared $407, flipping that area into a support zone. The short-term trend remains upward, but traders are watching for signs of pressure near the next resistance levels.

Breakout Holds as Price Approaches Resistance

ZEC is moving toward the 0.382 Fibonacci retracement level at $472. This area may act as near-term resistance. If the price breaks through, traders are likely to watch the $525 and $616 levels next. These zones align with previous ranges where the price has paused or reversed in the past.

The 50-period moving average around $357 has offered support on the way up. On the 4-hour chart, this level marks the midpoint of the recent trend.

Zcash (ZEC) price chart
Zcash (ZEC) price chart 09.12. Source: TradingView

Meanwhile, the RSI is at 69, near the overbought zone. Momentum is strong, but the current reading suggests the pace may slow before a clear next move develops.

Whales Buy as Retail Sells

Recent data shared by analyst Ardi shows different behavior between retail and institutional players. According to him, “Retail ($0–$1k) and mid-sized ($1k–$100k) accounts are aggressively selling,” while wallets holding $100k to $10M are increasing their positions.

Over $30 million in smaller account holdings were sold recently, while larger wallets bought $100 million in the same time. Ardi described the move as “institutional absorption”, with large buyers picking up supply being sold at market. He added,

In a separate view, analyst BeLaunch noted a price rejection near $425. This was followed by lower volume on the advance and reduced positioning from short-term holders. While 24-hour holders are still active, capital flow data showed a mixed picture. Derivatives saw outflows, while spot markets recorded new inflows.

New Fee Proposal and ETF Conversion Plans

Additionally, the Zcash development team has proposed a change to the way fees work during periods of congestion. The update would base transaction fees on the median of the last 50 blocks. A 10x fee lane would allow priority transactions during high demand. The rollout will happen in phases. The upgrade is expected to go through a consensus change, without a full redesign.

Separately, Grayscale submitted a proposal to convert its Zcash Trust into an ETF last month, as we reported. If approved, this could allow traditional investors access to ZEC exposure through a regulated product without needing to hold the asset.

The post Zcash (ZEC) Price Jumps 24% Weekly: Is $616 the Next Target? appeared first on CryptoPotato.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09